Board Meeting Intimation for Board Meeting For Adoption Of Unaudited Financial Results For The Quarter Ended June 30, 2018 Along With Limited Review Report Thereon
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2018 ,inter alias, to consider and approve Board Meeting for adoption of Unaudited Financial Results for the Quarter ended June 30, 2018 along with Limited Review Report thereon Shareholding for the Period Ended June 30, 2018
Rubra Medicaments Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2018. For more details, kindly Click here Statement Of Investor Complaints For The Quarter Ended June 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Abha KapoorDesignation :- Director Appointment Of CDSL As A Designated Depository For The Purpose Of Monitoring The Foreign Investment Limit
Appointment Of CDSL as A Designated Depository For The Purpose Of Monitoring The Foreign Investment Limit Board Meeting Scheduled To Be Held On Monday, May 28, 2018.
Board Meeting scheduled to be held on Monday, May 28, 2018. Certificate Under Regulation 40 (10) Of The SEBI (LODR) Regulations, 2015 For The Half Year Ended March 31, 2018
Certificate Under Regulation 40 (10) Of The SEBI (LODR) Regulations, 2015 For The Half Year Ended March 31, 2018 Compliance Certificate For The Year Ended March 31, 2018
Compliance Certificate For The Year Ended March 31, 2018 Shareholding for the Period Ended March 31, 2018
Rubra Medicaments Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2018. For more details, kindly Click here